German authorities approve third clinical trial of COVID-19 vaccine - Times Now
"Trials on vaccine candidates in humans are a significant step in the direction of authorizing safe and efficacious vaccines against COVID-19," PEI noted.
Berlin: Germany's Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich-Institut (PEI), approved the third clinical trial of a potential COVID-19 vaccine on Friday. The vaccine candidate was developed by the German Center for Infection Research (DZIF) and the pharmaceutical company IDT Biologika. During the Phase-1 trial, 30 healthy adult volunteers between 18 and 55 years would receive two vaccinations at a four-week interval, according to PEI. "Trials on vaccine candidates in humans are a significant step in the direction of authorizing safe and efficacious vaccines against COVID-19," PEI noted. The candidate is a vector vaccine for which the genetic information for a surface protein of SARS-CoV-2 is built into a smallpox virus, according to PEI. The vaccine against the smallpox virus had already been developed more than 30 years ago at the Ludwig-Maximilians-University Munich (LMU). The vector could not replicate in the body of the vaccinated person, but the genetic information introduced could simulate an infection and trigger the production of COVID-19 antibodies and immune cells, according to PEI. The German government launched a special funding program to accelerate research and development of a COVID-19 vaccine, with up to 750 million euros (878 million U.S. dollars). The clinical trial of the vaccine candidate by IDT Biologika and DZIF is one of three trials currently conducted by German companies in the fight against COVID-19. The pharmaceutical companies BioNTech and CureVac are already conducting studies in advanced phases in trials on humans.
Russian Sputnik V COVID-19 vaccine offers immunity after first shot: Developer - Times Now
The Sputnik V coronavirus vaccine delivers immunity in some people after the first vaccination against the SARS-CoV-2 virus that causes COVID-19, says developer.
- On August 11, the Sputnik V vaccine was registered by the Ministry of Health of Russia, becoming the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform
- Post-registration trials involving 42, 000 people of the Russian Sputnik V coronavirus vaccine are currently underway
- The first results of these trials are expected to be released in October-November 2020
Can you have COVID-19 even if you test negative for coronavirus? - Times Now
Doctors say a person may test negative for COVID-19, but that doesn't always mean he or she is clear of coronavirus. What could be the factors causing false negative test results?
Can you have COVID-19 even if you test negative for coronavirus? Can you have COVID-19 even if you test negative for coronavirus? Key Highlights
- People infected with coronavirus can still test negative for COVID-19, the disease caused by the SARS-CoV-2 virus
- Doctors say it's important to treat patients based on clinical symptoms and not the reports
- So, what could be the reason behind these false negative results?
- Molecular tests to detect the genetic material of SARS-CoV-2.
- Antigen tests, a new category of tests that can detect fragments of the virus from nasal swabs quickly.
- Antibody tests that can tell you if you’ve had a past infection.
COVID-19 vaccine: AstraZeneca and Moderna leading the race, says WHO - Times Now
"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.
Geneva: AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday. The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford. This week, AstraZeneca signed its tenth supply-and-manufacturing deal. "Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference. "So it's possible they will have results quite early." Swaminathan said Moderna's COVID-19 vaccine candidate was "not far behind" AstraZeneca's, among more than 200 candidates, 15 of which have entered clinical trials. "We do know that Moderna's vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind," she said. "But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials." The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, as well as with Indian researchers, Swaminathan said. She called for drugmakers to consider collaborating on COVID-19 vaccine trials, similar to the WHO's ongoing Solidarity trial for drugs. A WHO-led coalition fighting the pandemic on Friday asked government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments and vaccines for the disease. The initiative is called the ACT-Accelerator. Andrew Witty, Special Envoy for the ACT-Accelerator, said it was important to consider a "portfolio of research efforts" for vaccines. "It's still very early days in this journey, we may be super lucky - which would be terrific - and have an early win," Witty said. "Even if it takes 12 to 18 months that would be without precedent, the world's fast development of vaccine."